←Multiple Sclerosis
Study register · detail Querschnittsbefragung (anonymer Survey) · Multiple Sclerosis · 1997

The perceived effects of smoked cannabis on patients with multiple sclerosis.

Consroe et al. ·European Neurology Impact 1.1
Clear benefit GRADE Low 325 citations
Samplen = 112 Pat.
EndpointSelf-reported symptom…
Blindingn.a.
DesignQuerschnittsbefragung (anonymer Survey)
Cannabinoidvollspektrum
Routeinhalativ
Key finding

Most respondents reported subjective symptom relief from cannabis, most frequently for spasticity and chronic pain.

Summary

n=112 MS patients (53 UK + 59 USA), anonymous questionnaire on cannabis use. 97–30% reported improvement (descending): spasticity (97%), chronic limb pain, acute paroxysms, tremor, emotional dysfunction, anorexia/weight loss. Results served as a basis for planning clinical trials.

P
PopulationPersons with multiple sclerosis (MS) from UK and USA, n=112 (53 UK, 59 USA)
I
InterventionSelf-reported use of smoked cannabis (self-report of respondents)
O
Outcome97–30% of respondents reported subjective improvement in spasticity, chronic pain, tremor, emotional dysfunction, fatigue, bladder/bowel symptoms, among others
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Consroe P, Musty R, Rein J, Tillery W, Pertwee R.
DOI 10.1159/000112901↗
Design: Querschnittsbefragung (anonymer Survey)
Share
Abstract
Fifty-three UK and 59 USA people with multiple sclerosis (MS) answered anonymously the first questionnaire on cannabis use and MS. From 97 to 30% of the subjects reported cannabis improved (in descending rank order): spasticity, chronic pain of extremities, acute paroxysmal phenomenon, tremor, emotional dysfunction, anorexia/weight loss, fatigue states, double vision, sexual dysfunction, bowel and bladder dysfunctions, vision dimness, dysfunctions of walking and balance, and memory loss. The MS subjects surveyed have specific therapeutic reasons for smoking cannabis. The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms.
Indication
Further studies on Multiple Sclerosis
All studies →
S Filippini et al. · 2022 · The Cochrane database of systematic reviews
73 citations
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Mixed Systematic Review

Cochrane Systematische Review zu Cannabinoiden bei MS-Symptomen (Spastik, chronischer neuropathischer Schmerz); Suchzeitraum bis Dezember 2021. Evaluierte Reduktion ≥30% auf Spastik-NRS und ≥50% Schmerzlinderung als primäre Outcomes. Einschluss von RCTs mit synthetischen, pflanzlichen und Herbal-Cannabis-Präparaten; Evidenzbewertung nach GRADE durchgeführt.

10.1002/14651858.cd013444.pub2 View study →
S Nielsen et al. · 2018 · Current neurology and neuroscience reports
146 citations
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
Mixed Systematic Review

Umbrella Review über k=11 systematische Reviews zu Cannabinoiden bei MS-Symptomen (Daten aus 32 Studien, darunter 10 moderate bis hochwertige RCTs). Fünf Reviews schlossen auf ausreichende Evidenz für Wirksamkeit bei Schmerz und/oder Spastik. Schlussfolgerung: Cannabinoide können moderate Effekte auf MS-assoziierte Schmerzen oder Spastik haben; Evidenz für andere Symptome (Behinderungsprogression, Tremor/Ataxie, Blasenfunktion, Lebensqualität) unzureichend.

10.1007/s11910-018-0814-x View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; moderate Evidenz für MS-Spastik (Nabiximols reduziert Spastik-NRS um -0,12 Punkte vs. Placebo, CI -0,24 bis 0,01), basierend auf mehreren Phase-III-Studien.

10.1001/jama.2015.6358 View study →

The impediment to action advances action. — Marcus Aurelius